Evidence map›Paper›PMID 26842989›Full record

ReviewJournal of genetics and genomics = Yi chuan xue bao2016

The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer.

Jingwu Xie, Xiaoli Zhang

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of genetics and genomics = Yi chuan xue bao, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jingwu XieDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA; The Simon Cancer Center and The Wells Center for Pediatrics Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA. Electronic address: jinxie@iu.edu.
Xiaoli ZhangDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN 46202, USA; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA; Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA; The Simon Cancer Center and The Wells Center for Pediatrics Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Indiana University – Purdue University Indianapolis · US

Funding

Molecular Basis of Hedgehog Signaling in CarcinogenesisR01CA094160 · NCI · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI XIE, JINGWU · 2002 to 2011
$2.8M
Regulation of immune surveillance by hedgehog signaling in tumor microenvironmentR01CA155086 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI XIE, JINGWU · 2012 to 2016
$1.6M
NCI NIH HHS R01 CA094160NCI NIH HHS R01 CA155086NCI NIH HHS R01CA155086NCI NIH HHS R01CA94160
6 · The paper itself

Abstract

There is high expectation for significant improvements in cancer patient care after completion of the human genome project in 2003. Through pains-taking analyses of genomic profiles in cancer patients, a number of targetable gene alterations have been discovered, with some leading to novel therapies, such as activating mutations of EGFR, BRAF and ALK gene fusions. As a result, clinical management of cancer through targeted therapy has finally become a reality for a subset of cancers, such as lung adenocarcinomas and melanomas. In this review, we summarize how gene mutation discovery leads to new treatment strategies using non-small cell lung cancer (NSCLC) as an example. We also discuss possible future implications of cancer genome analyses.

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungGenomicsHumansLung NeoplasmsMolecular Targeted TherapyMutationPractice Guidelines as TopicProtein Kinase InhibitorsProtein-Tyrosine KinasesAntineoplastic AgentsProtein Kinase InhibitorsProtein-Tyrosine KinasesGene mutationLung cancerTargeted therapy

Identifiers

PMID26842989
PMCPMC5161107
OpenAlexW1704321731

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.